Share on StockTwits

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued to investors on Tuesday. They currently have a $27.90 price target on the stock. Zacks‘s price target points to a potential downside of 4.88% from the company’s current price.

A number of other firms have also recently commented on ANIP. Analysts at Oppenheimer raised their price target on shares of ANI Pharmaceuticals from $35.00 to $37.00 in a research note on Tuesday, August 5th.

ANI Pharmaceuticals (NASDAQ:ANIP) traded down 2.59% during mid-day trading on Tuesday, hitting $28.57. 110,856 shares of the company’s stock traded hands. ANI Pharmaceuticals has a 1-year low of $6.84 and a 1-year high of $38.74. The stock has a 50-day moving average of $29.82 and a 200-day moving average of $30.95. The company has a market cap of $323.2 million and a price-to-earnings ratio of 53.04.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings data on Monday, August 4th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.01 by $0.22. The company had revenue of $6.60 million for the quarter, compared to the consensus estimate of $7.95 million. The company’s quarterly revenue was up 8.0% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals will post $0.97 earnings per share for the current fiscal year.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.